A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.

Donovan, Joanne M; Zimmer, Michael; Offman, Elliot; Grant, Toni; Jirousek, Michael.
J Clin Pharmacol; 57(5): 627-639, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28074489